Colorectal Cancer

John Marshall, MD, recently discussed the treatment options and decisions he makes when treating patients with metastatic colorectal cancer. Marshall explained his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.

Lung Cancer

According to results from the CALGB 8903 study published in the <em>Journal of Clinical Oncology, </em>there is an association between total nut intake and improved outcomes in patients with stage III colon cancer. Results of the study showed patients who ate at least 2 servings of nuts per week had superior disease-free survival and overall survival.

Michael A. Morse, MD, discusses a number of key trials that have broadened the treatment landscape of mCRC, the importance of toxicity management in this setting, and other ongoing developments in GI cancers.

Clinical Approach for Left-Sided Metastatic Colorectal Cancer

Progression of Left-Sided Metastatic Colorectal Cancer

Even as immunotherapy grows more popular as a treatment for solid tumors, physicians are racing to identify patients with the molecular subtypes, rather than the disease, who will derive the most benefit.

Ulixertinib, a novel ERK1/2 inhibitor, demonstrated encouraging antitumor activity in patients with solid tumors harboring mutations in the MAPK/ERK pathway, according to the results of a phase I study published in <em>Cancer Discovery</em>.